The rise of Antimicrobial Resistance (AMR) calls for resistance-breaking antibiotics and complementary approaches to fight this public health threat. Whilst there are some promising signs with increasing awareness in governments including at G7/G20 level, renewed interest from industry with direct investments and the AMR Action fund and testing of new reimbursement “pull Incentive" models, the pipeline of investable new products remains weak.
INCATE is a new, virtual and the only European based not-for-profit partnership supporting specifically antimicrobial resistance (AMR)-related innovations (TRL 1-4). INCATE addresses particularly the problem of an insufficient flow of early innovation by supporting the transfer of academic discoveries to investible biotech start-ups and creating a viable ecosystem encouraging young investigators particularly in the AMR-field, which suffers due to poor economical attractiveness, while innovative antimicrobial concepts are desperately sought after. Our goal is to cure currently insufficient clinical development pipelines with urgently needed antimicrobial concepts to waive the global danger of resistant pathogens.